分享产品介绍 评论(0)
物种
Mouse分子别名
TNFRSF7, T14, S152, Tp55, Cluster of differentiation 27Accession
P41272表达序列
Thr21-Arg182 with Human IgG1 Fc at the C-Terminus表达宿主
HEK293分子量
50-70kDa (Reducing)
纯度
>95% by SDS-PAGE, RP-HPLC&SEC-HPLC内毒素含量
<0.1EU/μg活性
Immobilized CD27 Fc Chimera Protein, Mouse (Cat. No. UA011079) at 5.0μg/mL (100μL/well) can bind CD27 LigandTNFSF7 His Tag, Mouse with EC50 of 27.86-39.99ng/mL.标记
Unconjugated标签
Human IgG1 Fc性状
Lyophilized Powder缓冲体系
PBS, pH7.4, 5% trehalose
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
文献引用
Drner T. et al. (2004) Correlation of circulating CD27 high plasma cells and disease activity in systemic lupus erythematosus. Lupus. 13(5): 283-289.
Sahota S S. et al. (2009) CD27 in defining memory B-cell origins in Waldenstrm's macroglobulinemia. Clin Lymphoma Myeloma. 9(1): 33-35.
Jiang J. et al. (2010) Reduced CD27 expression on antigen-specific CD4+ T cells correlates with persistent active tuberculosis. J Clin Immunol. 30(4): 566-573.
Cluster of Differentiation 27 (CD27) is a member of the Tumor Necrosis Factor Receptor superfamily and is integral to T-cell activation, providing a crucial costimulatory signal. When CD27 binds to its natural ligand, CD70, it enhances T-cell proliferation and the differentiation of effector and memory T cells. This interaction holds potential as an immune modulatory target for cancer treatment.
The CD27 agonistic antibody, varlilumab, has demonstrated promising efficacy in both hematological malignancies and solid tumors. Current research is focused on studying the combination therapy of varlilumab with PD-1 axis inhibitors, such as nivolumab or atezolizumab, which target immune checkpoint pathways.
Furthermore, CD70 expression is being explored as a therapeutic target for Antibody-Drug Conjugates (ADCs), antibodies that induce Antibody-Dependent Cellular Cytotoxicity (ADCC), as well as for chimeric antigen receptor (CAR) gene-modified T cells and specific dendritic cell vaccinations.
Clinical trials have shown that targeting the CD27 axis is feasible and safe, with the most common side effects being thrombocytopenia, fatigue, and nausea.
电泳
1μg (R: reducing condition).
体积排阻色谱(SEC-HPLC)
The purity of CD27 Fc Chimera Protein, Mouse is more than 95% determined by SEC-HPLC.
反相高效液相色谱(RP-HPLC)
The purity of CD27 Fc Chimera Protein, Mouse is more than 95% determined by RP-HPLC.
ELISA
Immobilized CD27 Fc Chimera Protein, Mouse (Cat. No. UA011079) at 5.0μg/mL (100μL/well) can bind CD27 LigandTNFSF7 His Tag, Mouse with EC50 of 27.86-39.99ng/mL.
Immobilized CD27 Fc Chimera Protein, Mouse (Cat. No. UA011079) at 2.0μg/mL (100μL/well) can bind Biotinylated CD27 Ligand/TNFSF7 Fc Chimera Protein, Human with EC50 of 5.99-8.93 ng/mL.
评论(0)